Ask AI
Individualized Treatment of Advanced EC

CME

New Directions in Individualized Treatment of Advanced Endometrial Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 11, 2025

Expiration: March 10, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following therapies has shown promising activity in combination with letrozole in patients with recurrent/metastatic ER+ EC?

2.

A woman with advanced endometrial cancer and disease progression after platinum-based chemotherapy and a PD-L1 inhibitor has come in for a consultation. Her ECOG PS is 1 and she is interested in clinical trials. Which of the following biomarkers would you explain to her is required to be eligible for the phase III ASCENT-GYN-01 trial of sacituzumab govitecan vs TPC chemotherapy?